{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037968","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.220272+00:00","generated_at":"2026-06-12T08:07:39.012882+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sight Sciences Q2 revenue $23.5M (+36% YoY); net loss narrows to $14.8M; reaffirms FY guidance","bullets":["Revenue $23.5M, +36% YoY; Surgical Glaucoma $21.4M (+35%), Dry Eye $2.1M (+56%).","Net loss $14.8M ($0.30/share) vs $23.8M ($0.50) prior year; operating expenses down 6%.","Gross margin 85.6% (vs 84.1% prior year); cash $154.5M; long-term debt $35.0M.","FY2023 revenue guidance reaffirmed at $89-94M (25-32% YoY growth); quarterly adjusted opex ~$30.5M.","SAHARA trial met primary signs endpoint at 6 months; Cigna covers OMNI procedures (15M lives)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037968","json":"https://secwatch.observer/filing/0000950170-23-037968.json","markdown":"https://secwatch.observer/filing/0000950170-23-037968.md","text":"https://secwatch.observer/filing/0000950170-23-037968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023037968/0000950170-23-037968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023037968/sght-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:07:39.012882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfd6d3048fb0dd54f16d7f90d6ab7735dadbf0c6","claim":"Sight Sciences, Inc. reported the second quarter ended June 30, 2023 results: revenue $23.5 million. Guidance reaffirmed.","evidence_excerpt":"second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights • Generated record second quarter 2023 total revenue of $23.5 million, an increase of 36% compared to the prior year period • Achieved total gross margin of 85.6% in the second quarter of 2023 compared to 84.1% in the prior year period Dry Eye","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023037968/0000950170-23-037968-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$23.5 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}